Dapagliflozin for Heart Failure: SGLT2 Inhibitor Trends & Research
Okay,here’s a breakdown of the reference list entries you provided,extracting key details from each:
Reference 37:
* Authors: Ronco,C; Haapio,M; House,AA; Anavekar,N; Bellomo,R
* Title: Cardiorenal syndrome
* Journal: J Am Coll Cardiol
* DOI: 10.1016/j.jacc.2008.07.051
* Volume: 52
* Issue: 19
* Pages: 1527-39
* Year: 2008
Reference 38:
* Author: Brenner BM
* Title: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease
* Journal: Kidney Int
* DOI: 10.1038/ki.1983.72
* volume: 23
* Issue: 4
* Pages: 647-55
* Year: 1983
Reference 39:
* Authors: Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al.
* Title: Spironolactone for heart failure with preserved ejection fraction
* Journal: N Engl J Med
* Volume: 370
* Issue: 15
* Pages: 1383-92
* Year: 2014
Observations:
* the references are formatted in a standard bibliographic style.
* Each entry includes author(s), title, journal, and publication details (volume, issue, pages, year).
* The entries also include links to various databases (google Scholar, PubMed, CAS, Article) for further information.
* The rel="nofollow noopener" attribute on the links suggests that these are external links and the website owner doesn’t necessarily endorse the content.
* The data-track attributes indicate that clicks on these links are being tracked for analytics purposes.
